

January 03, 2023

To,
Department of Corporate Services,
BSE Limited
Ground Floor, P.J.Tower,
Dalal Street, Fort,
Mumbai- 400001

**BSE Script Code: 541735** 

**Subject: Outcome of Board Meeting** 

Dear Sir/Madam,

In continuation of our letter Dated December 26, 2022, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday January 03, 2023 at Registered Office of the Company has inter alia considered and approved the following:

## 1. Postponement of Preferential Issue of equity warrants:

During the period under review, the company has shown growing performance and continues to grow in the same phase. With the upsurge of COVID situation internationally the pharmaceutical industry is going to outperform compared to other industries. Presently the company is traded at the PE of around 21 despite certain strict conditions and therefore the valuations which have been derived for the preferential issue based on the SEBI Guidelines does not give due respect to the intrinsic value of equity share. The Board has further observed that with the surge of Covid situation and possibility of impending restrictions in India, timely implementation of the project may be impacted. The impact of time on the outcomes we hope to achieve may be disordered and result in financial loss to the company. In the present scenario the Board took a strict & clear decision to postpone the issue of equity warrant and upcoming expansion project till the situation favors the company.

## 2. The Board of Directors with the above postponement decision also called off the ensuing Extra Ordinary General Meeting scheduled to be held on Tuesday January 17, 2023.

You are requested to take the above information on your record.

The Board Meeting commenced at 6:30 p.m. and concluded at 7:00 p.m.

## For, Vivanta Industries Limited

Sweta Sandip Digitally signed by Sweta Sandip Prajapati Date: 2023-01-03

Sweta Prajapati Company Secretary & Compliance Officer Membership No.: A66245